Emerson Electric Co. $EMR Shares Bought by Concurrent Investment Advisors LLC - MarketBeat
π Emerson Electric reported quarterly EPS of $1.71, beating the $1.68 consensus estimate, while revenue reached $4.87 billion versus expectations of $4.80 billion.
π¦ Concurrent Investment Advisors LLC increased its stake in EMR by 21.5% in Q2, bringing total holdings to 66,724 shares valued at approximately $9.55 million.
π° The company declared a quarterly dividend of $0.555 per share, equivalent to a $2.22 annualized yield of 1.5%, payable on September 10th.
π Analysts maintain a 'Moderate Buy' consensus with an average price target of $167.83, supported by recent upgrades from JPMorgan Chase and Royal Bank of Canada.
π CEO Surendralal Karsanbhai sold 9,650 shares for approximately $1.56 million in early August, representing a 3.43% decrease in his personal ownership.
π§ Emerson operates through two principal platforms: Automation Solutions and Commercial & Residential Solutions, focusing on industrial automation and climate control technologies.
π Institutional ownership stands at 74.3%, with several other funds like Rooted Wealth Advisors and Cary Street Partners increasing their positions in Q4.
π The stock has a market capitalization of $85.63 billion, a PE ratio of 33.45, and a beta of 1.24, trading between a one-year low of $122.64 and high of $166.35.
π KeyCorp decreased its price objective on EMR from $185.00 to $170.00 while maintaining an 'overweight' rating in a July report.
π DA Davidson lifted its price target from $145.00 to $155.00 but assigned a 'neutral' rating in an August research note.
- Emerson Electric beat quarterly EPS estimates of $1.68 with actual results of $1.71, demonstrating operational resilience.
- Revenue reached $4.87 billion, exceeding analyst expectations of $4.80 billion despite flat year-over-year growth.
- Concurrent Investment Advisors LLC significantly increased its stake by 21.5% in Q2, adding 11,802 shares to its portfolio.
- Multiple institutional investors including Rooted Wealth Advisors and Cary Street Partners increased their holdings in Q4.
- The company maintained its fiscal 2026 EPS guidance at $6.55, signaling confidence in future performance.
- JPMorgan Chase upgraded EMR from 'neutral' to 'overweight' with a price target of $157.00.
- Royal Bank of Canada boosted its price target to $179.00 and assigned an 'outperform' rating.
- The company declared a quarterly dividend of $0.555 per share, providing a 1.5% yield to shareholders.
- CEO Surendralal Karsanbhai sold 9,650 shares for approximately $1.56 million in early August.
- KeyCorp decreased its price objective on EMR from $185.00 to $170.00 in a July report.
- DA Davidson lifted its price target but assigned a 'neutral' rating, indicating caution.
- Revenue growth was flat year-over-year at 0%, suggesting limited top-line expansion in the quarter.